National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 64545 [2019-25304]
Download as PDF
<![CDATA[
Federal Register / Vol. 84, No. 226 / Friday, November 22, 2019 / Notices
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel;
NIMH: Limited Competition for a
Connectome Coordination Facility.
Date: December 10, 2019.
Time: 12:30 p.m. to 1:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center Building (NSC), 6001
Executive Boulevard, Rockville, MD 20852
(Telephone Conference Call).
Contact Person: Vinod Charles, Ph.D.,
Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, NIH, Neuroscience Center,
6001 Executive Blvd., Room 6151, MSC 9606,
Bethesda, MD 20892–9606, 301–443–1606,
charlesvi@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.242, Mental Health Research
Grants, National Institutes of Health, HHS)
Dated: November 18, 2019.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–25303 Filed 11–21–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
khammond on DSKJM1Z7X2PROD with NOTICES
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The cooperative agreement
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the cooperative agreement applications,
the disclosure of which would
VerDate Sep<11>2014
16:57 Nov 21, 2019
Jkt 250001
constitute a clearly unwarranted
invasion of personal privacy.
64545
451 7th Street SW, Room 10282,
Washington, DC 20410–0500, telephone
202–708–5300 (this is not a toll-free
Name of Committee: National Institute of
number). Persons with hearing- or
Allergy and Infectious Diseases Special
speech-impairments may access this
Emphasis Panel; HIV/AIDS Prevention
number through TTY by calling the tollClinical Trials Network Leadership and
Operations Center (UM1—Clinical Trial
free Federal Relay Service at 800–877–
Required).
8339.
Date: December 11, 2019.
For information concerning a
Time: 12:00 p.m. to 4:00 p.m.
particular waiver that was granted and
Agenda: To review and evaluate
for which public notice is provided in
cooperative agreement applications.
this document, contact the person
Place: National Institutes of Health, 5601
whose name and address follow the
Fishers Lane, Rockville, MD 20892
description of the waiver granted in the
(Telephone Conference Call).
accompanying list of waivers that have
Contact Person: Kumud K. Singh, Ph.D.,
Scientific Review Officer, Scientific Review
been granted in the third quarter of
Program, Division of Extramural Activities,
calendar year 2019.
National Institutes of Health, NIAID, 5601
SUPPLEMENTARY INFORMATION: Section
Fishers Lane, MSC–9823, Rockville, MD
106 of the HUD Reform Act added a
20852, 301–761–7830, kumud.singh@
new section 7(q) to the Department of
nih.gov.
Housing and Urban Development Act
(Catalogue of Federal Domestic Assistance
(42 U.S.C. 3535(q)), which provides
Program Nos. 93.855, Allergy, Immunology,
that:
and Transplantation Research; 93.856,
1. Any waiver of a regulation must be
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS) in writing and must specify the grounds
for approving the waiver;
Dated: November 15, 2019.
2. Authority to approve a waiver of a
Tyeshia M. Roberson,
regulation may be delegated by the
Program Analyst, Office of Federal Advisory
Secretary only to an individual of
Committee Policy.
Assistant Secretary or equivalent rank,
[FR Doc. 2019–25304 Filed 11–21–19; 8:45 am]
and the person to whom authority to
BILLING CODE 4140–01–P
waive is delegated must also have
authority to issue the particular
regulation to be waived;
DEPARTMENT OF HOUSING AND
3. Not less than quarterly, the
URBAN DEVELOPMENT
Secretary must notify the public of all
waivers of regulations that HUD has
[Docket No. FR–6164–N–03]
approved, by publishing a notice in the
Federal Register. These notices (each
Notice of Regulatory Waiver Requests
covering the period since the most
Granted for the Third Quarter of
recent previous notification) shall:
Calendar Year 2019
a. Identify the project, activity, or
AGENCY: Office of the General Counsel,
undertaking involved;
HUD.
b. Describe the nature of the provision
ACTION: Notice.
waived and the designation of the
provision;
SUMMARY: Section 106 of the Department
c. Indicate the name and title of the
of Housing and Urban Development
person who granted the waiver request;
Reform Act of 1989 (the HUD Reform
d. Describe briefly the grounds for
Act) requires HUD to publish quarterly
approval of the request; and
Federal Register notices of all
e. State how additional information
regulatory waivers that HUD has
about a particular waiver may be
approved. Each notice covers the
obtained.
quarterly period since the previous
Section 106 of the HUD Reform Act
Federal Register notice. The purpose of also contains requirements applicable to
this notice is to comply with the
waivers of HUD handbook provisions
requirements of section 106 of the HUD
that are not relevant to the purpose of
Reform Act. This notice contains a list
this notice.
of regulatory waivers granted by HUD
This notice follows procedures
during the period beginning on July 1,
provided in HUD’s Statement of Policy
2019 and ending on September 30,
on Waiver of Regulations and Directives
2019.
issued on April 22, 1991 (56 FR 16337).
In accordance with those procedures
FOR FURTHER INFORMATION CONTACT: For
and with the requirements of section
general information about this notice,
106 of the HUD Reform Act, waivers of
contact Aaron Santa Anna, Acting
regulations are granted by the Assistant
Associate General Counsel for
Legislation and Regulations, Department Secretary with jurisdiction over the
regulations for which a waiver was
of Housing and Urban Development,
PO 00000
Frm 00093
Fmt 4703
Sfmt 4703
E:\FR\FM\22NON1.SGM
22NON1
]]>Agencies
[Federal Register Volume 84, Number 226 (Friday, November 22, 2019)]
[Notices]
[Page 64545]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-25304]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The cooperative agreement applications and the
discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with the cooperative agreement
applications, the disclosure of which would constitute a clearly
unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; HIV/AIDS Prevention Clinical Trials
Network Leadership and Operations Center (UM1--Clinical Trial
Required).
Date: December 11, 2019.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate cooperative agreement
applications.
Place: National Institutes of Health, 5601 Fishers Lane,
Rockville, MD 20892 (Telephone Conference Call).
Contact Person: Kumud K. Singh, Ph.D., Scientific Review
Officer, Scientific Review Program, Division of Extramural
Activities, National Institutes of Health, NIAID, 5601 Fishers Lane,
MSC-9823, Rockville, MD 20852, 301-761-7830, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: November 15, 2019.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2019-25304 Filed 11-21-19; 8:45 am]
BILLING CODE 4140-01-P
